1- Ministry of health and population (Egypt), El-Zanaty and associates (Egypt) and ICF international (2014) Egypt demographic and health survey. Egypt and Rockville, Maryland, USA.
2- European Association for the Study of the Liver (2018) EASL recommendations on treatment of hepatitis C. Journal of hepatology 69 (2): 461-511.
3- Abd Alla, MDA, & El Awady MK (2017) Hepatitis C virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serum PCR naïve and post-treatment patients. J Clin &Transl Hepatol 5:1-8.
4- Nelson DR, Roth D, Bruchfeld A, Liapaki A, Silv M, Monsour JH, et al (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet 386 (10003): 1537-1545.
5- Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown Jr, et al (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149: 649-59.
6- Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, et al (2015) Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Alimentary pharmacology & therapeutics 41(7): 671-685.
7- Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al (2016) Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 151(3): 457-471.
8- Abd Alla MDA, Gomaa AA, Farrag GAA, Shikhroho MG, Mousa WM, Mahmoud OA (2018) Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin. Al-Azhar Assiut Medical Journal 16 (2): 197-204.
9- Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY (2020) Huang JF. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. Journal of gastroenterology and hepatology 35 (1): 151-156.
10- Vasilios P, Stylianos K (2015) Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 3(3): 210-220.
11- Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E (2015) Role of genetic polymorphisms in hepatitis C virus chronic infection. World Journal of Clinical Cases: WJCC 3 (9): 807-822.
12-Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, et al (2016) IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus 5 (1): 1-13.
13-Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S et al (2011) Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 31: 891-899.
14- Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S et al (2011) IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54:716-722.
15-Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58:1548–1557.
16- Shousha HI, Awad AH, Omran DA, Elnegouly MM, Mabrouk M (2018) Data mining machine learning algorithms using IL28B genotype and biochemical markers best predicted advanced liver fibrosis in chronic HCV. Japanese journal of infectious diseases 71 (1): 51-57.
17- D’Ambrosio R, Aghemo A, De Francesco R, Rumi MG, Galmozzi E, De Nicola S, et al (2014) The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci 15: 7213-7224.
18- Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, et al (2011) Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54:1127-1134.
19- Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, et al (2012) IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55: 384-394.
20- Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, et al (2012) IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 97: 679-686.
21- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
22- Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-80
23- Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al (2010) Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53: 439-443
24- Rembeck K, Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, et al 2012) Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 7: e29370
25- Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al (2012). HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142: 978-988
26- Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, et al (2013) Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 62(9): 1340-1346.
27- Zhang Y, Zhu SL, Chen J, Li LQ (2016) Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma. Onco Targets Ther 9: 3249-3257
28- Khan AJ, Saraswat VA, Ranjan P, Parmar D, Negi TS, Mohindra S (2019) Polymorphism in interferon λ3/interleukin‐28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. Journal of medical virology 91 (4): 659-667.
29- Salum GM, Dawood RM, el-Meguid MA, Ibrahim NE, Aziz AOA, El Awady MK (2019) Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes & Diseases 5(4): 1-9 DIO:10.1016/j.gendis.2019.05.004
30- Hanno AFF, Mohiedeen KM, Alshayeb AF, Deghedy A (2014) HCV RNA in peripheral blood mononuclear cells (PBMCs) as a predictor of the response to antiviral therapy in chronic hepatitis C. Alexandria Journal of Medicine 50: 317- 322.
31- Elzahaby AAA, Soliman GMM, Korany MA, Eltiby DM, El Awady MK (2017) Association Between Post Treatment Existence Of HCV/ RNA Positive Strand And/Or Negative Strand In The PBMCs and HCV Relapse. Journal of the Egyptian Society of Parasitology 47(2): 323- 330
32- Abd Alla MDA, Dawood RM, Rashed HA, Farrag G, Ammar IAE, Mahmoud MMA, et al (2021) Treatment of Hepatitis C virus (HCV) by Direct Acting Antivirals (DAAs) Plus Ribavirin Eliminates Intra-Peripheral Blood Mononuclear Cells (PBMCs) Viral RNA and Reduces Virologic Relapse in Diverse Hepatic Parenchymal Changes. Journal Archives of Virology 166(4), 1071-1081, DOI 10.1007/s00705-021-04969-4
33- Hashmi AH, Husnain MA, Farooq A, Khalid K, Shafique S, Adeel K, et al (2018) IL28B is An Irrelevant Prognostic Factor for HCV in the Era of Highly Effective DAAs. J Virol Antivir Res 7 (2): 1-4. doi: 10.4172/2324-8955.1000186
34- Chomczyński P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chlotoform extraction. Anal Biochem 162: 156-159
35- Zaman N, Asad MJ, Raza A, Raja GK, Akhter S, Mahmood M, et al (2014) Presence of HCV RNA in peripheral blood mononuclear cells may predict patient‟s response to interferon and ribavirin therapy. Ann Saudi Med 34 (5): 401-406.
36- Abd Alla MDA, Elibiary SA, Wu GY, El-Awady MK (2017) Occult HCV infection (OCI) diagnosis in cirrhotic and non-cirrhotic naïve patients by intra-PBMC nested viral rNA PCR. J Clin & Transl Hepatol 5: 319-326.
37- Abd Alla MDA, El Awady MK, Dawood RM, Elhawary MA, Al-Azhari, SS, Galal ASG (2018) Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. Archives of virology 163(10): 2765-2774
38- El-Awady MK, Abdel Rahman MM, Ismail SM, Amr KS, Omran M, Mohamed SA (2003) Prediction of relapse after interferon therapy in hepatitis C virus-infected patients by the use of triple assay. J Gastroenterol Hepatol 18: 68-7339.
39- Wahab EA, Fathy T, Saber S, Ahmad HS (2017) Hepatic Elastography And Fib-4 Score Versus Liver Biopsy For Assessment Of Liver Fibrosis In Chronic Hcv Patients. Zagazig University Medical Journal 21: 1-11.
40- Abd Alla, MDA., & El Awady MK (2017) Hepatitis C virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serum PCR naïve and post-treatment patients. J Clin&Transl. Hepatol 5:1-8.
41- Abd Alla MDA, Elibiary SA, Elshaboury RH, Wu GY, Dawood RM, El Awady MK (2018) HCV Therapy follow-up fractionation (CTF2) by intra-PBMC nested RNA PCR recognizes early virologic response and relapse. J clin and trans hepatology 6(2): 1-8.